OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

July 7th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.

Dr. Chi on Combinations with Androgen Deprivation Therapy for Prostate Cancer

July 7th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses combinations with androgen deprivation therapy for patients with prostate cancer.

Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer

July 7th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

Dr. Arend on the PORTEC-3 Trial for Endometrial Cancer

July 7th 2017

Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses the PORTEC-3 trial for patients with endometrial cancer.

Dr. Siegel on the Treatment of HPV-Associated Head and Neck Cancer

July 7th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the treatment for patients with HPV-associated head and neck cancer.

Dr. Huffman on Survival Analysis of Patients With Pseudopapillary Tumors of the Pancreas

July 7th 2017

Brandon Huffman, MD, resident physician, internal medicine, Mayo Clinic, discusses the survival analysis from a study of patients with solid pseudopapillary tumors of the pancreas.

Dr. von Minckwitz on the Safety Profile of the APHINITY Trial for HER2+ Breast Cancer

July 7th 2017

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the safety profile of the phase III APHINITY trial for patients with HER2-positive breast cancer.

Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

July 7th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

Dr. Somaiah on NY-ESO-1 Expression in Soft Tissue Sarcoma

July 7th 2017

Neeta Somaiah, MD, assistant professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the expression of NY-ESO-1 in patients with soft tissue sarcoma.

Dr. Oyer on Tools for Clinicians to Use When Treating Patients With Cancer

July 6th 2017

Randall A. Oyer, MD, oncology program, medical director, Lancaster General Health, treasurer, Association of Community Cancer Centers, discusses some of the tools clinicians could potentially use for their patients with cancer.

Dr. Modest on Study of Surgical Intervention in CRC

July 6th 2017

Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.

Dr. Garon on Future of Immunotherapy in NSCLC

July 6th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the future of immunotherapy in the paradigm of non–small cell lung cancer (NSCLC).

Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer

July 6th 2017

Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction cancer.

Dr. Stephenson on Patient Preferences on Undergoing Active Surveillance for Prostate Cancer

July 6th 2017

Andrew Stephenson, MD, director of Urologic Oncology, Cleveland Clinic, discusses patient preferences with undergoing active surveillance versus active treatment for their prostate cancer.

Dr. Siegel Discusses RT-Related AEs for Patients With Oropharyngeal Squamous Cell Carcinomas

July 6th 2017

Robert Siegel, MD, chair, professor of medicine, director, Division of Hematology/Oncology, George Washington University, discusses the adverse events (AEs) associated with radiation therapy (RT) for patients with oropharyngeal squamous cell carcinomas.

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

July 6th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

Dr. Kumar Discusses Ixazomib in Multiple Myeloma

July 5th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.

Dr. Yang on the Efficacy of Immunotherapy in Follicular Lymphoma

July 5th 2017

Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.

Dr. Tam on the Toxicities of Ibrutinib Plus Venetoclax in MCL

July 5th 2017

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities of the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Dr. Brufsky on CDK 4/6 Inihibitors in Neoadjuvant Breast Cancer Treatment

June 29th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.